logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Optimism: The Market is Rebounding and Biotech Firms Inspiring News

The Market Soared Being optimistic about the greatness of American scientific capability does not mean underestimating the coronavirus' ability to infect, devastate and threaten human lives. Today the market is rebounding from the fear that caused the stock market to...

Read More

March 2, 2020

0

Fighting COVID-19. See Also: Stocks Gains Following the Market's Rebounding

Treating and Preventing COVID-19 Treating COVID-19, Gilead Sciences With regard to treating patients with COVID-19 we believe the most expected product to be used during this virus' outbreak will be Gilead Sciences’ ( GILD ) product remdesivir . This product...

Read More

March 5, 2020

0

Hepion Pharmaceuticals' Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Hepion Pharmaceuticals CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...

Read More

October 17, 2019

0

Market Frustration, Volatility and Chaos

Stock Market Fluctuations and Volatility  Only history can remind us that what’s going on recently with the stock market is not new. Similar situations have taken place during the terms of every president since Ronald Reagan. Indeed, the same stock...

Read More

March 12, 2020

0

A Market in Chaos. Moderna's Human Trial Began Today

A Market in Chaos The Market is in chaos. When this happens the market needs to be stopped from causing massive unwarranted harm to countries' economies, the firms and investors in the stock market. A healthy market does not drop...

Read More

March 16, 2020

0

We Introduce UroGen Pharma and Discuss Its Pipeline of Products

Presenting UroGen Pharma UroGen Pharma ( URGN ) focuses on cancers and urologic diseases. It announced its fourth quarter and full-year ended December 31, 2019 financial results. The announcement started with Liz Barrett, President and Chief Executive Officer (CEO) of UroGen...

Read More

April 2, 2020

0

The Time Has Come for Us To Present Fate Therapeutics

Presenting Fate Therapeutics Today we are presenting Fate Therapeutics ( FATE );  a clinical-stage company developing programmed cellular immunotherapies for cancer and immune disorders. Our enthusiasm for this firm is due to its announcement that it signed a global collaboration...

Read More

April 3, 2020

0

Novavax: A Hand-Picked Vaccine on the Road Towards Human Clinical Trial Against Coronavirus

Novavax Identified an "Ideal" Coronavirus Vaccine Candidate The news from Novavax ( NVAX ) informs that the firm has identified an "ideal" coronavirus vaccine candidate, NVX-CoV2373 , that is a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology. The...

Read More

April 8, 2020

0

Be Careful NOT to Underestimate the Following Biotech Stocks (Part 1)

Halozyme and PTC Therapeutics: Near-Term Game-Changing PDUFAS Some of the Prohost Portfolio selected companies are having near term PDUFAS which we believe will have a positive outcome. Indeed the FDA approvals are expected to tremendously boost these firms' values. Today...

Read More

April 24, 2020

0

Be Careful NOT to Underestimate the Following Biotech Stocks (Part 2)

Theravance Biopharma: Near-Term Game-Changing PDUFAS Some of the Prohost Portfolio selected companies are having near term PDUFAS which we believe will have a positive outcome. Indeed we expect the FDA approvals to tremendously boost these firms’ values.  I n Part...

Read More

April 26, 2020

0

  • Previous
  • 1
  • 2
  • 3
  • 4
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy